November 10, 2026, 10:30 AM – 12:00 PM EST
The past decade has delivered an extraordinary range of oncology therapeutic modalities—next-gen ADCs, bispecifics, T-cell engagers, allogeneic cell therapies, antibody-like TCRs, endogenous reprogramming approaches, and vaccines. Each brings unique strengths, and increasingly the question isn’t which modality is universally “best,” but which is best fit for purpose; for a specific target, line of therapy, patient population, or combination/sequencing strategy.
The session is intended to elucidate some of the key issues in strategizing around positioning, clinical development and market opportunity that biotechs (and pharma) must address, regardless of stage of development, to optimize value of the asset. Picking up the conversation started at our BIO 2026 panel, “Battle of the Modalities in Oncology: One Size Fits All or Fit to Purpose?” diving deeper into how biotechs and pharma companies, regardless of development stage, should strategize around positioning, clinical development, and market opportunity to maximize asset value.
Our expert panel will tackle tumor heterogeneity and resistance, frontline versus later-line applicability, sequencing and combination strategies, differentiation in a crowded competitive landscape, the tension between investor priorities and scientific direction, first-in-class versus best-in-class considerations, and the emerging influence of China-based innovation and AI on oncology drug development.
You’ll walk away with:
- A sharper framework for early clinical development strategy decisions
- Clearer insight into how clinical strategy connects to market opportunity and ROI
- A more credible narrative for articulating value inflection points to investors and partners
Join us for a candid, cross-disciplinary discussion designed for anyone shaping the future of oncology therapeutics.